Preliminary experience of initial and re-administration of nimustine as a new primary treatment for feline nasal lymphoma a case report

• Published in: Japanese Journal of Veterinary Research Vol. 72; no. 2; pp. 56 - 64
• Main Authors: Goda, Yoshimichi, Hidaka, Yuichi, Goto, Mifumi, Inoue, Yoshiyuki, Kuroda, Kohei, Nakatake, Yuki, Sato, Reiichiro, Satoh, Hiroyuki
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Journal of Veterinary Research Editorial Committee 30.10.2024; Faculty of Veterinary Medicine, Hokkaido University
• Subjects: cat; nasal lymphoma; nimustine
• ISSN: 0047-1917; 2758-447X
• DOI: 10.57494/jjvr.72.2_56

A 5-year-old spayed female domestic short haired cat presented with chronic nasal obstruction. The cat was diagnosed with B-cell nasal lymphoma based on histological examination of biopsy specimens and intracranial invasion was suspected. We initiated treatment with nimustine (ACNU), known to pass the blood–brain barrier, as the primary protocol with prednisolone, with the owner’s consent. The ACNU dose was 20–25 mg/m² (4–5-week intervals, four or six administrations, two courses). The cat remained oligosymptomatic until day 962 after the first dose and no serious adverse events were reported. The cat lived until day 1089. To our knowledge, this is the first report of long-term survival achieved using ACNU as the primary treatment in a cat with nasal lymphoma.